📚 Central Nervous System Special Senses Module L2 Leprosy And Borillia

📚 Lecture Overview

This lecture covers two key bacterial pathogens that cause peripheral and central nervous system infections: Mycobacterium leprae (the causative agent of leprosy) and Borrelia burgdorferi (the causative agent of Lyme disease). It details their unique microbiological characteristics, mechanisms of nerve damage, clinical manifestations, diagnostic methods, and treatment protocols. Understanding these infections is critical for diagnosing bacterial neuropathies and managing vector-borne and chronic peripheral nerve diseases.

🎯 Key Concepts & Definitions

• Mycobacterium leprae: An obligate intracellular, acid-fast bacterium that causes leprosy and specifically targets peripheral Schwann cells.
• Borrelia burgdorferi: A helical, motile spirochete transmitted by Ixodes ticks that causes Lyme disease and Lyme neuroborreliosis.
• Acid-Fast Stain (Ziehl-Neelsen): A differential staining technique used to identify bacteria with high cell wall lipid content, such as mycolic acids.
• Schwann Cells: Peripheral nervous system glial cells targeted by M. leprae, leading to demyelination and nerve damage.
• Neuroborreliosis: Neurological involvement occurring during disseminated or late stages of B. burgdorferi infection.
• Erythema Migrans: The characteristic bull's-eye skin rash that appears at the site of a tick bite in early localized Lyme disease.
• Multidrug Therapy (MDT): A combination drug regimen (rifampicin, dapsone, and clofazimine) used to treat leprosy and prevent drug resistance.

📖 Main Content

1. Mycobacterium leprae & Leprosy

Microbiology & Growth Characteristics

• Morphology: Rod-shaped, acid-fast bacterium due to a high lipid content in its cell wall (specifically mycolic acids).
• Replication: Extremely slow replication with a doubling time of approximately 14 days.
• Growth: Cannot be cultured in artificial media; it is an obligate intracellular bacterium.
• Temperature Preference: Grows preferentially in cooler body regions, such as the skin and peripheral nerves.
• Laboratory Models: Armadillos and mouse footpads are used to cultivate and study the organism.

Transmission & Incubation

• Transmitted via prolonged close contact, likely through respiratory droplets or contact with skin lesion exudates.
• The incubation period is prolonged—symptoms may take up to 20 years to develop.

Pathogenesis & Mechanism of Nerve Damage

• Host Immune Response: Clinical spectrum depends entirely on cell-mediated immunity (CMI):
• Tuberculoid Leprosy: Strong cell-mediated immune response; low bacterial load; negative acid-fast stains; positive lepromin skin test.
• Lepromatous Leprosy: Weak cell-mediated immune response; widespread bacterial dissemination; high bacterial load.
• Nerve Damage Mechanism:
  1. M. leprae has a specific predilection for Schwann cells in the peripheral nervous system.
  2. The bacterium binds to laminin-2 on Schwann cells via a specific surface protein.
  3. This binding triggers demyelination and subsequent axonal damage.

M. leprae Surface Protein  --->  Binds Laminin-2 on Schwann Cells  --->  Demyelination & Axonal Damage  --->  Sensory & Motor Deficits

Nervous System Manifestations

• Peripheral Neuropathy: Hallmark feature presenting as loss of sensation or numbness, especially in extremities.
• Motor Neuropathy: Causes muscle weakness and atrophy.
• Autonomic Dysfunction: Causes anhidrosis (loss of sweating), leading to dry, cracked skin susceptible to secondary bacterial infections.
• Nerve Thickening: Affected nerves become visibly thickened and palpable (e.g., ulnar, median, and peroneal nerves).

Diagnosis & Treatment

• Clinical Diagnosis: Hypopigmented skin lesions with sensory loss and thickened peripheral nerves.
• Laboratory Diagnosis: Skin biopsies stained with Ziehl-Neelsen demonstrate acid-fast bacilli.
• Lepromin Skin Test: Positive in the tuberculoid form (indicates strong CMI); negative in lepromatous leprosy.
• Treatment: Multidrug Therapy (MDT) consisting of rifampicin, dapsone, and clofazimine.

2. Borrelia burgdorferi & Lyme Disease (Neuroborreliosis)

Microbiology & Transmission

• Morphology: Helical (spiral-shaped), motile spirochete.
• Motility: Driven by periplasmic flagella, enabling movement through viscous environments like host connective tissue.
• Growth: Microaerophilic and grows very slowly on specialized media.
• Vector: Transmitted by the bite of infected Ixodes ticks during the summer. Most common vector-borne illness in the US and Europe.

Dissemination & Immune Evasion

• Spreads from the bite site via the bloodstream and lymphatic system to joints, heart, and nervous system.
• Evades host immunity and promotes chronic tissue inflammation by changing surface antigens (antigenic variation) and forming immune complexes.

Clinical Stages of Lyme Disease

Manifestations of Neuroborreliosis

1. Meningitis: Lymphocytic meningitis presenting with headache, neck stiffness, and photophobia.
2. Cranial Neuritis: Most common cranial neuropathy is facial nerve palsy (Bell's palsy). May also cause visual disturbances or hearing loss.
3. Peripheral Neuropathy: Numbness, tingling, and pain due to nerve inflammation and demyelination.

Diagnosis & Treatment

• Serology: ELISA to detect antibodies against B. burgdorferi (may be negative in early stage 1).
• CSF Analysis:
• Lymphocytic pleocytosis (increased white blood cells)
• Elevated protein levels
• Normal glucose levels
• Presence of intrathecal antibodies against B. burgdorferi
• PCR: Detects Borrelia DNA in CSF.
• Treatment Regimen:
• Early-stage Lyme: Oral doxycycline or amoxicillin.
• Late/Severe Neuroborreliosis: Intravenous ceftriaxone.

📊 Visual Learning

Diagram 1: M. leprae Pathogenesis & Nerve Injury

Diagram 2: Stages of Lyme Disease Progression

Diagram 3: Diagnostic Findings in Neuroborreliosis CSF

💡 Important Points to Remember

• M. leprae cannot be grown on artificial media; it requires living hosts (armadillos or mouse footpads).
• M. leprae specifically targets Schwann cells by binding to laminin-2.
• Nerve damage in leprosy leads to anhidrosis (autonomic loss), causing dry skin and secondary infections.
• Palpably thickened nerves (ulnar, median, peroneal) are a key clinical diagnostic indicator of leprosy.
• Multidrug Therapy (MDT) for leprosy consists of three drugs: rifampicin, dapsone, and clofazimine.
• Borrelia burgdorferi uses periplasmic flagella to navigate through viscous connective tissue.
• Facial nerve palsy (Bell's palsy) is the most common cranial neuropathy in Lyme disease.
• Erythema migrans (bull's-eye rash) is the classic pathognomonic feature of Stage 1 Lyme disease.
• CSF profile in Lyme meningitis: Lymphocytic pleocytosis, high protein, but NORMAL glucose.
• Stage 3 Lyme disease can clinically mimic multiple sclerosis.
• Treatment choice depends on Lyme severity: Oral Doxycycline/Amoxicillin for early stages; IV Ceftriaxone for severe/late neuroborreliosis.

⚠️ Common Exam Questions & Traps

MCQ Traps & Tricks

• The Culture Media Trap: Question asks for the ideal agar/culture medium to grow Mycobacterium leprae.
• Trap: Providing options like Lowenstein-Jensen, Blood Agar, or Middlebrook.
• Fact: M. leprae cannot grow on artificial media. Select options mentioning armadillos or mouse footpads.
• The CSF Glucose Trap: Questions asking you to interpret CSF results in Lyme meningitis.
• Trap: Presenting low CSF glucose to trick you into assuming a standard acute bacterial meningitis pattern.
• Fact: Neuroborreliosis CSF shows lymphocytic pleocytosis and high protein, but glucose is normal.
• Lepromin Skin Test Interpretation:
• Trap: Expecting a positive skin test in Lepromatous leprosy because it has a high bacterial load.
• Fact: Lepromin skin test relies on Cell-Mediated Immunity (CMI). It is positive in Tuberculoid leprosy (strong CMI) and negative in Lepromatous leprosy (weak CMI).
• Early Serology Negativity:
• Trap: A patient presents 3 days after a tick bite with Erythema Migrans, but Lyme ELISA is negative. Question asks for next step.
• Fact: Serology can be false-negative in early Stage 1. Clinical diagnosis guides early management.

Common Short Answer Questions

• Contrast Tuberculoid vs. Lepromatous Leprosy: Focus on immune response (strong vs. weak CMI), bacterial load, acid-fast stain results, and Lepromin test reactivity.
• Compare Antibiotic Management for Lyme Disease: Differentiate between early localized treatment (oral doxycycline/amoxicillin) and severe/late neuroborreliosis (IV ceftriaxone).

📝 Quick Review Checklist

I can explain why M. leprae cannot be cultured in standard lab media and list its animal models.
I understand the molecular target (laminin-2 on Schwann cells) involved in leprosy nerve injury.
I can list the three drugs used in Multidrug Therapy (MDT) for leprosy.
I can state the differences between tuberculoid and lepromatous leprosy regarding CMI and lepromin test results.
I can identify the vector (Ixodes tick) and bacterial morphology (spirochete with periplasmic flagella) of B. burgdorferi.
I can outline the three clinical stages of Lyme disease and their representative features (e.g., Erythema migrans, Bell's palsy).
I know the key CSF findings in Lyme neuroborreliosis (lymphocytes elevated, high protein, normal glucose).
I can specify the appropriate antibiotics for early vs. late/severe Lyme disease.